|
BioPharma Dive
@
BioPharmaDive
Washington, D.C.
|
|
We provide business journalism and in-depth insight into the most impactful news and trends shaping biotech and pharma. Sign up here: dive.pub/_BD9
|
|
|
13.246
Tweetovi
|
343
Pratim
|
9.903
Osobe koje vas prate
|
| Tweetovi |
|
BioPharma Dive
@BioPharmaDive
|
14 h |
|
$REGN hopes to replicate its past success in quickly advancing a treatment for Ebola. But, as that experience showed, proving a new antiviral isn't easy.
biopharmadive.com/news/regeneron…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
15 h |
|
$GILD acknowledged the cell therapy developer is worth less than it once thought, cutting the accounting value for research assets it acquired by $800M
biopharmadive.com/news/gilead-ye…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
15 h |
|
With $200M more in bank, $AIMT also in-licensed an experimental next-generation food allergy therapy from $XNCR
biopharmadive.com/news/nestle-ai…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
16 h |
|
A yet-to-be-named new company will house $MRK's women's health, biosimilar and legacy drugs, providing space and resources for the pharma's higher-growth businesses.
biopharmadive.com/news/merck-joi…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
4. velj |
|
Anteros Pharmaceuticals is the first company made via a partnership between $BMY and biotech accelerator BioMotiv. Its initial targets are liver and lung fibrosis, with one specific focus being IPF.
biopharmadive.com/news/bristol-m…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
4. velj |
|
$PFE, $GSK and $AGN were the most active, collectively raising list prices on some 450 drugs this Jan., according to one Wall Street analyst.
biopharmadive.com/news/january-d…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
4. velj |
|
HHS and $REGN previously worked together on an experimental Ebola treatment that proved effective in the 2018 outbreak of that disease.
biopharmadive.com/news/regeneron…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
3. velj |
|
$AIMT's next challenge will be securing insurance coverage as people allergic to peanuts still have to avoid exposure to the food.
biopharmadive.com/news/aimmune-f…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
3. velj |
|
With biologics driving growth, $CTLT is looking to diversify with a $315M purchase that hands it a slate of production sites.
biopharmadive.com/news/catalent-…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
3. velj |
|
Research into preventive treatments will continue, however, as an NIH leader declared a vaccine "essential" to ending the widespread disease.
biopharmadive.com/news/nih-stop-…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
3. velj |
|
$GILD will work with Chinese authorities to test its drug remdesivir, while $GSK is providing its adjuvant platforms to groups partnered with CEPI.
biopharmadive.com/news/gilead-gs…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
31. sij |
|
With $420M in Q4 revenues, $VRTX's cystic fibrosis drug Trikafta performed 5x better than expected — and capped off an 8-year growth story for the biotech's CEO.
biopharmadive.com/news/vertex-tr…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
31. sij |
|
Too few women and people of color are in executive positions or on the boards of biotech companies, according to a new report from BIO.
biopharmadive.com/news/biotech-d…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
31. sij |
|
Competition is heating up for copycats to $RHHBY's top-selling cancer drugs, as the U.S. biosimilar market shows some modest signs of shifting $AMGN $PFE $BIIB
biopharmadive.com/news/amgen-pfi…
|
||
|
|
||
| BioPharma Dive proslijedio/la je tweet | ||
|
Jacob Bell
@realJacobBell
|
31. sij |
|
If you haven't yet, check out @BioPharmaDive's latest deep dive. After years being all-in on brain drugs, big pharma pulled back. Is a return on the horizon? And, if so, what effects might it have on drug research? #biotech #pharma #neuroscience biopharmadive.com/news/pharma-ne…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
30. sij |
|
Spinraza rivals and Tecfidera patent challenges were in the spotlight as $BIIB provided few details about its planned filing for aducanumab.
biopharmadive.com/news/biogen-ea…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
30. sij |
|
$LLY's top scientist, however, set low expectations the drug will show a clear benefit.
biopharmadive.com/news/lilly-pre…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
29. sij |
|
Biotech execs see a new era of neuroscience advances ahead.
But it's hard to pinpoint what would cause pharma to dive back in — and what ripples that would create.
biopharmadive.com/news/pharma-ne…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
29. sij |
|
The Third Rock-backed company put an acting executive in place as it repositions for development in gene therapy and regenerative medicine.
biopharmadive.com/news/decibel-c…
|
||
|
|
||
|
BioPharma Dive
@BioPharmaDive
|
29. sij |
|
Another 100 infants received $NVS' Zolgensma in the fourth quarter, supported by broad insurance coverage and more newborn screening.
biopharmadive.com/news/novartis-…
|
||
|
|
||